ReviewFrontiers in aging neuroscience2026
Neuroprotective role of bilirubin in Parkinson's disease.
Review in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The progressive loss of dopaminergic neurons in the nigrostriatal pathway, driven by mechanisms such as oxidative stress, neuroinflammation, and ferroptosis, represents a hallmark of Parkinson's disease (PD). Notably, physiological or mildly elevated bilirubin levels demonstrate potent antioxidant and anti-inflammatory properties. This positions bilirubin as a compelling endogenous molecule with potential neuroprotective significance in PD. Furthermore, emerging evidence links early embryonic neurodevelopmental impairments to long-term PD risk, revealing a new dimension for protective interventions. Methods: This review synthesizes current evidence on the protective roles of bilirubin against PD, detailing its mechanisms in countering oxidative stress, modulating neuroinflammation, inhibiting ferroptosis, and supporting normal development of nigrostriatal dopaminergic circuits. Key molecular pathways-including Nrf2 activation, microglial polarization, and developmental signaling pathways such as Wnt/β-catenin and Shh-are critically examined. Results: Our analysis demonstrates that bilirubin directly neutralizes reactive species, preserves mitochondrial integrity, and promotes an anti-inflammatory milieu by inducing M2 microglia and modulating T-cell populations. Bilirubin also mitigates dopaminergic neuron injury by reducing iron deposition and activating the Nrf2 pathway. Beyond these classical mechanisms, bilirubin may fundamentally shape PD risk by orchestrating early embryonic development of dopaminergic neurons through key morphogenic signals, thereby ensuring robust neural circuit formation. Discussion: This review explores the multifaceted potential of bilirubin, framing it not only as a neuroprotectant against established PD pathologies but also as a developmental modulator. By integrating insights from neural development and classical neurodegeneration, this work will inspire future translational research into bilirubin-based therapeutic strategies to prevent or modify the progression of PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.